All In Biotech

Drug Trial Radar · NCT01817530

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

571

Actual

Start

Apr 8, 2013

Primary completion

Jun 2015

Study completion Dec 2015

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 51 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.

Conditions

  • Heavy Uterine Bleeding
  • Uterine Fibroids

Interventions

  • Elagolix placeboOther

    oral coated tablet

  • ElagolixDrug

    oral coated tablet

  • 0.5 mg estradiol / 0.1 mg norethindrone acetateDrug

    oral hard capsule

  • 1 mg estradiol / 0.5 mg norethindrone acetateDrug

    oral hard capsule

  • E2/NETA placeboDrug

    oral hard capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final MonthTime frame: Baseline, Final Month (last 28 days of treatment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.